Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation

被引:12
作者
Dhédin, N
Chamakhi, I
Perreault, C
Roy, DC
Sauvageau, G
Ducruet, T
Busque, L
Fish, D
Bélanger, R
Roy, J
机构
[1] Hop Maison Neuve Rosemont, Div Hematol, Montreal, PQ H1T 2M4, Canada
[2] Univ Montreal, Montreal, PQ H3C 3J7, Canada
[3] Hop La Pitie Salpetriere, Div Hematol, Paris, France
[4] Boreal Primum, Montreal, PQ, Canada
关键词
D O I
10.1016/j.exphem.2005.09.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Risk factors of acute graft-vs-host disease (GVHD) following allogeneic bone marrow transplantation have been well described before. In this study, we tested the hypothesis that acute GVHD after allogeneic peripheral blood stem cell (PBSC) transplant might be associated with donors' responsiveness to granulocyte colony-stimulating factor (G-CSF), rather than the dose of CD34(+) cells infused. Patients and Methods. We retrospectively analyzed mobilization and transplant data (demographic characteristics, donor blood cell subsets after G-CSF, graft composition) in 149 consecutive HLA-identical donor/recipient pairs in order to identify acute GVHD risk factors. Results. In 25% of donors, G-CSF mobilization led to an outstanding response, defined as greater than 117 x 10(6) CD34(+) cells/L. Overall, incidence of grades II-IV acute GVHD was 20.1% (95 % CI: 16.6-23.6). Following univariate analysis, the incidence increased significantly in recipients receiving greater than 10 x 10(6) CD34(+) cells/kg (35% vs 15%; p = 0.007), and those transplanted from outstanding mobilizers (41% vs 12%,p < 0.0001). In multivariate analysis, only transplantation from outstanding mobilizers remained significant (P = 0.02). Donor or recipient demographic characteristics and lymphocyte subsets reinfused in the graft had no impact. Conclusions. We demonstrate for the first time that donor responsiveness to G-CSF is associated with acute GVHD following PBSC transplantation. If confirmed, this correlation will help to identify recipients who could potentially benefit from improved prophylaxis. As further corollary, decreasing the dose of CD34(+) cells infused is unlikely to prevent acute GVHD. Future studies should focus on the molecular bases of interindividual discrepancies in response to G-CSF. (c) 2006 International Society for Experimental Hematology.
引用
收藏
页码:107 / 114
页数:8
相关论文
共 37 条
  • [1] Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim
    Anderlini, P
    Przepiorka, D
    Seong, C
    Smith, TL
    Huh, YO
    Lauppe, J
    Champlin, R
    Korbling, M
    [J]. TRANSFUSION, 1997, 37 (05) : 507 - 512
  • [2] Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.
    Bensinger, WI
    Martin, PJ
    Storer, B
    Clift, R
    Forman, SJ
    Negrin, R
    Kashyap, A
    Flowers, MED
    Lilleby, K
    Chauncey, TR
    Storb, R
    Appelbaum, FR
    Rowley, S
    Heimfeld, S
    Blume, K
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (03) : 175 - 181
  • [3] Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation
    Bittencourt, H
    Rocha, V
    Chevret, S
    Socié, G
    Espérou, H
    Devergie, A
    Dal Cortivo, L
    Marolleau, JP
    Garnier, F
    Ribaud, P
    Gluckman, E
    [J]. BLOOD, 2002, 99 (08) : 2726 - 2733
  • [4] Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Societe Francaise de Greffe de Moelle
    Blaise, D
    Kuentz, M
    Fortanier, C
    Bourhis, JH
    Milpied, N
    Sutton, L
    Jouet, JP
    Attal, M
    Bordigoni, P
    Cahn, JY
    Boiron, JM
    Schuller, MP
    Moatti, JP
    Michalle, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) : 537 - 546
  • [5] BROSS DS, 1984, BLOOD, V63, P1265
  • [6] CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies
    Cao, TM
    Wong, RM
    Sheehan, K
    Laport, GG
    Stockerl-Goldstein, KE
    Johnston, LJ
    Shizuru, JA
    Negrin, RS
    Lowsky, R
    [J]. EXPERIMENTAL HEMATOLOGY, 2005, 33 (03) : 279 - 285
  • [7] A randomized multicenter comparison of CD34+-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies
    Cornelissen, JJ
    van der Holt, B
    Petersen, EJ
    Vindelov, L
    Russel, CA
    Höglund, M
    Maertens, J
    Schouten, HC
    Braakman, E
    Steijaert, MMC
    Zijlmans, MJM
    Slaper-Cortenbach, I
    Boogaerts, MA
    Löwenberg, B
    Verdonck, LF
    [J]. EXPERIMENTAL HEMATOLOGY, 2003, 31 (10) : 855 - 864
  • [8] A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies
    Couban, S
    Simpson, DR
    Barnett, MJ
    Bredeson, C
    Hubesch, L
    Kang, HL
    Shore, TB
    Walker, IR
    Browett, P
    Messner, HA
    Panzarella, T
    Lipton, JH
    [J]. BLOOD, 2002, 100 (05) : 1525 - 1531
  • [9] CD34+cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation
    Díez-Campelo, M
    Pérez-Simón, JA
    Ocio, EM
    Castilla, C
    González-Porras, JR
    Sánchez-Guijo, FM
    Vázquez, L
    Caballero, MD
    Cañizo, MC
    San Miguel, JF
    [J]. LEUKEMIA & LYMPHOMA, 2005, 46 (02) : 177 - 183
  • [10] Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial
    Flowers, MED
    Parker, PM
    Johnston, LJ
    Matos, AVB
    Storer, B
    Bensinger, WI
    Storb, R
    Appelbaum, FR
    Forman, SJ
    Blume, KG
    Martin, PJ
    [J]. BLOOD, 2002, 100 (02) : 415 - 419